A. von Heydebreck

发表

Prognostic Role of E2F1 and Members of the CDKN2A Network in Gastrointestinal Stromal Tumors

Florian Haller, Holger Sültmann, H. Sültmann, 2005, Clinical Cancer Research.

Maximum likelihood estimation of oncogenetic tree models.

B. Gunawan, A. von Heydebreck, L. Füzesi, 2004, Biostatistics.

Genome-Wide Array Analysis of Normal and Malformed Human Hearts

Martin Vingron, Hans Lehrach, Jan Vogel, 2003, Circulation.

Parameter estimation for the calibration and variance stabilization of microarray data

A. Poustka, W. Huber, M. Vingron, 2003, Statistical applications in genetics and molecular biology.

Mucin 1-specific active cancer immunotherapy with tecemotide (L-BLP25) in patients with multiple myeloma: An exploratory study

H. Mellstedt, A. von Heydebreck, A. Österborg, 2014, Human vaccines & immunotherapeutics.

Transcription profiling of renal cell carcinoma.

A. Poustka, M. Vingron, H. Sültmann, 2002, Verhandlungen der Deutschen Gesellschaft fur Pathologie.

Gene expression in kidney cancer is associated with cytogenetic abnormalities, metastasis formation, and patient survival.

Martin Vingron, Wolfgang Huber, Holger Sültmann, 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.

Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study

L. Dirix, L. Emens, M. Lippman, 2017, Breast Cancer Research and Treatment.

Updated efficacy of avelumab in patients with previously treated metastatic Merkel cell carcinoma after ≥1 year of follow-up: JAVELIN Merkel 200, a phase 2 clinical trial

K. Lewis, C. Lebbé, M. Milella, 2018, Journal of Immunotherapy for Cancer.

Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial.

G. Linette, K. Lewis, C. Lebbé, 2016, The Lancet. Oncology.

EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study.

K. O'Byrne, Keunchil Park, F. de Marinis, 2012, The Lancet. Oncology.

Localization‐ and mutation‐dependent microRNA (miRNA) expression signatures in gastrointestinal stromal tumours (GISTs), with a cluster of co‐expressed miRNAs located at 14q32.31

Ö. Sahin, S. Wiemann, F. Haller, 2010, The Journal of pathology.

Avelumab in patients with previously treated metastatic melanoma: phase 1b results from the JAVELIN Solid Tumor trial

J. Nemunaitis, L. Wyrwicz, Keun-Wook Lee, 2018, Journal of Immunotherapy for Cancer.

An oncogenetic tree model in gastrointestinal stromal tumours (GISTs) identifies different pathways of cytogenetic evolution with prognostic implications

F. Haller, B. Gunawan, A. von Heydebreck, 2007, The Journal of pathology.

Predictive value of epidermal growth factor receptor expression for first-line chemotherapy plus cetuximab in patients with head and neck and colorectal cancer: analysis of data from the EXTREME and CRYSTAL studies.

F. Hirsch, K. Kerr, E. Van Cutsem, 2013, European journal of cancer.

Prognostic impacts of cytogenetic findings in clear cell renal cell carcinoma: gain of 5q31-qter predicts a distinct clinical phenotype with favorable prognosis.

A. Poustka, T. Efferth, A. Heydebreck, 2001, Cancer research.

Relationship Between EGFR Expression, EGFR Mutation Status, and the Efficacy of Chemotherapy Plus Cetuximab in FLEX Study Patients with Advanced Non–Small-Cell Lung Cancer

K. O'Byrne, K. Kerr, F. Shepherd, 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Loss of 9p leads to p16INK4A down‐regulation and enables RB/E2F1‐dependent cell cycle promotion in gastrointestinal stromal tumours (GISTs)

A. Poustka, H. Sültmann, U. Korf, 2008, The Journal of pathology.

Reproducibility of immunohistochemical scoring for epidermal growth factor receptor expression in non-small cell lung cancer: round robin test.

T. Molina, A. Marx, K. Kerr, 2013, Archives of pathology & laboratory medicine.

Origin and pathogenesis of nodular lymphocyte–predominant Hodgkin lymphoma as revealed by global gene expression analysis

Martin-Leo Hansmann, Brunangelo Falini, Verena Brune, 2008, The Journal of experimental medicine.

Cytogenetic and morphologic typing of 58 papillary renal cell carcinomas: evidence for a cytogenetic evolution of type 2 from type 1 tumors.

G. Jakse, B. Gunawan, A. von Heydebreck, 2003, Cancer research.

Identification and Classification of Differentially Expressed Genes in Renal Cell Carcinoma by Expression Profiling on a Global Human 31 , 500-Element cDNA Array

M Vingron, A. Poustka, S. Haas, 2001 .

Efficacy and Safety of Avelumab for Patients With Recurrent or Refractory Ovarian Cancer: Phase 1b Results From the JAVELIN Solid Tumor Trial

K. Kelly, A. Heydebreck, J. Grewal, 2019, JAMA oncology.

Efficacy and Safety of Avelumab Treatment in Patients With Advanced Unresectable Mesothelioma: Phase 1b Results From the JAVELIN Solid Tumor Trial

J. Nemunaitis, C. Verschraegen, A. von Heydebreck, 2019, JAMA oncology.

Pharmacogenomic and pharmacoproteomic studies of cetuximab in metastatic colorectal cancer: biomarker analysis of a phase I dose-escalation study.

F. J. Ramos, J. Baselga, F. Rojo, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Expression of p16INK4A in gastrointestinal stromal tumours (GISTs): two different forms exist that independently correlate with poor prognosis

A. Agaimy, F. Haller, B. Gunawan, 2010, Histopathology.

Avelumab in patients with previously treated metastatic adrenocortical carcinoma: phase 1b results from the JAVELIN solid tumor trial

R. Claus, A. von Heydebreck, J. Gulley, 2018, Journal of Immunotherapy for Cancer.

Oncogenetic tree models based on cytogenetic data: new insights into the development of epithelial tumors of the thymus.

Roland Penzel, Herwart F Otto, Gunhild Mechtersheimer, 2005, Cancer genetics and cytogenetics.

Meta-analysis of individual patient data from randomized trials of chemotherapy plus cetuximab as first-line treatment for advanced non-small cell lung cancer.

K. O'Byrne, T. Lynch, F. Shepherd, 2014, Lung cancer.

Equivalence test in quantitative reverse transcription polymerase chain reaction: confirmation of reference genes suitable for normalization.

Florian Haller, Holger Sültmann, Bettina Kulle, 2004, Analytical biochemistry.

Site‐independent prognostic value of chromosome 9q loss in primary gastrointestinal stromal tumours

C. Enders, B. Gunawan, A. von Heydebreck, 2004, The Journal of pathology.

Avelumab (MSB0010718C; anti-PD-L1) in patients with recurrent/refractory ovarian cancer from the JAVELIN Solid Tumor phase Ib trial: Safety and clinical activity.

K. Kelly, G. Weiss, A. Heydebreck, 2016 .

Pharmacometric modeling and machine learning analyses of prognostic and predictive factors in the JAVELIN Gastric 100 phase III trial of avelumab

K. Venkatakrishnan, Akash Khandelwal, A. von Heydebreck, 2021, CPT: pharmacometrics & systems pharmacology.